- Home
- RNTX vs USIO Comparison
RNTX vs USIO Comparison
Compare RNTX & USIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNTX | USIO |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | United States | United States |
| Employees | 11 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 33.0M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | RNTX | USIO |
|---|---|---|
| Price | $1.30 | $1.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $10.00 | $4.00 |
| AVG Volume (30 Days) | ★ 94.8K | 49.3K |
| Earning Date | 05-14-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $28,200,535.00 |
| Revenue This Year | N/A | $15.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 12.69 |
| 52 Week Low | $1.02 | $1.03 |
| 52 Week High | $2.22 | $2.02 |
Technical Indicators
Market Signals| Indicator | RNTX | USIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 38.50 |
| Support Level | $1.06 | N/A |
| Resistance Level | $1.30 | $1.42 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 51.43 | 35.14 |
Price Performance
Historical ComparisonAbout RNTX Rein Therapeutics Inc.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.